Literature DB >> 9835068

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

H Rosing1, M J Hillebrand, J M Jimeno, A Gómez, P Floriano, G Faircloth, R E Henrar, J B Vermorken, E Cvitkovic, A Bult, J H Beijnen.   

Abstract

A method was developed for the bio-analysis of Ecteinascidin 743 (ET-743) using miniaturized liquid chromatography (LC) coupled to an electrospray ionization sample inlet (TurbolonSpray) and two quadrupole mass analyzers (LC/ESI-MS/MS). Solid-phase extraction was used as a sample pretreatment procedure. Ecteinascidin 743 is a very potent anticancer compound and is administered in microgram m-2 dosages, which demands special requirements in terms of sensitivity for the analytical method supporting clinical pharmacokinetic studies. Using conventional LC/UV, a lower limit of quantitation (LLQ) of 1 ng ml-1 plasma was reached using a 500 microliters sample volume, but LC/ESI-MS/MS permitted an LLQ of 10 pg ml-1. The latter method was found to be accurate and precise, and provided a broad linear concentration range of 0.010-2.50 ng ml-1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9835068     DOI: 10.1002/(SICI)1096-9888(1998110)33:11<1134::AID-JMS730>3.0.CO;2-S

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  9 in total

1.  Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.

Authors:  Laura Vidal; Margarita Magem; Clare Barlow; Beatriz Pardo; Amalia Florez; Ana Montes; Margarita Garcia; Ian Judson; Claudia Lebedinsky; Stan B Kaye; Ramón Salazar
Journal:  Invest New Drugs       Date:  2010-10-07       Impact factor: 3.850

2.  Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.

Authors:  Beatriz Pardo; Ramón Salazar; Eva Ciruelos; Hernán Cortés-Funes; Margarita García; Margarita Majem; Ana Montes; Carmen Cuadra; Arturo Soto-Matos; Claudia Lebedinsky; Vicente Alfaro; Luis Paz-Ares
Journal:  Med Oncol       Date:  2011-06-10       Impact factor: 3.064

3.  Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.

Authors:  Cristiana Sessa; Gianluca Del Conte; Alexandre Christinat; Sara Cresta; Antonella Perotti; Elisa Gallerani; Pilar Lardelli; Carmen Kahatt; Vicente Alfaro; Jorge L Iglesias; Carlos Fernández-Teruel; Luca Gianni
Journal:  Invest New Drugs       Date:  2013-03-07       Impact factor: 3.850

4.  Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

Authors:  J H Beumer; J M Rademaker-Lakhai; H Rosing; L Lopez-Lazaro; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

5.  Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.

Authors:  J H Beumer; N E Franke; R Tolboom; T Buckle; H Rosing; L Lopez-Lazaro; J H M Schellens; J H Beijnen; O van Tellingen
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

6.  Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

Authors:  Juan Jose Perez-Ruixo; Peter Zannikos; Sarapee Hirankarn; Kim Stuyckens; Elizabeth A Ludwig; Arturo Soto-Matos; Luis Lopez-Lazaro; Joel S Owen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar.

Authors:  Emilia Sawicki; Michel J Hillebrand; Hilde Rosing; Jan H M Schellens; Bastiaan Nuijen; Jos H Beijnen
Journal:  J Pharm Anal       Date:  2016-04-23

8.  Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.

Authors:  Takafumi Ueda; Shigeki Kakunaga; Masashi Ando; Kan Yonemori; Hideshi Sugiura; Kenji Yamada; Akira Kawai
Journal:  Invest New Drugs       Date:  2014-04-03       Impact factor: 3.850

Review 9.  Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

Authors:  Lotte van Andel; Hilde Rosing; Jan Hm Schellens; Jos H Beijnen
Journal:  Mar Drugs       Date:  2018-07-23       Impact factor: 5.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.